White Paper

Using Flexible Cohort Management To Enable Creativity In Oncology Designs

Source: 4G Clinical
Lab Worker Trial Design

The FDA is making a considerable effort to drive efficiencies in clinical trial research, especially when it comes to oncology studies. In 2017 alone, there were 46 new oncology drugs approved by the FDA, including 18 Fast Track Designated products and 17 Break-Through therapies.

The reason? Regulatory agencies recognise the standard way of conducting studies through rigid phases and designs are limiting drugs from reaching patients fast enough to address the unmet need. They are becoming more flexible about accepting positive results, allowing trial sponsors to be more creative with oncology designs.

With the support of the FDA, sponsors can follow the science. You should be able to change your protocol based on what is working. Especially with expensive drug. And even more expensive comparators and combination therapies. When you have positive signals, you should be able to pivot direction to build a global programme and gather the required data to prove it.

The challenge is that most clinical systems are not flexible enough to adapt to mid-study changes without trial disruption. To address these challenges, it is crucial for sponsors to have a robust RTSM and specifically cohort management functionality in place.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader